Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Gramza Website

Ann W. Gramza, M.D.

Selected Publications

1)  Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, Bible KC, Shah MH, Gramza AW, Klopper JP, Marlow LA, Heckman MG, Von Roemeling R.
Efatutazone, an oral PPAR-? agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.
J. Clin. Endocrinol. Metab. 98: 2392-400, 2013.
2)  Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu S, Bal C, Marur S, Gramza A, Ben-Yosef R, Gitlitz B, Haugen BR, Ondrey F, Lu C, Karandikar S, Khuri F, Licitra L, Remick SC.
Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma.
Thyroid. 24: 232-40, 2013.
3)  Gramza A, Kebebew E.
Cancer: thyroid cancer bone metastases and high morbidity rates.
Nat Rev Endocrinol. 8: 454-5, 2012.
4)  Sosa JA, Balkissoon J, Lu SP, Langecker P, Elisei R, Jarzab B, Bal CS, Marur S, Gramza A, Ondrey F.
Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer.
Surgery. 152: 1078-87, 2012.
5)  Gramza A, Schuff KG.
Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management.
Onco Targets Ther. 1: 87-101, 2009.
6)  Gramza AW, Corless CL, Heinrich MC.
Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors.
Clin. Cancer Res. 15: 7510-7518, 2009.
Click Here to View Expanded Bibliography.

This page was last updated on 2/25/2014.